Free Trial

Cormark Analysts Decrease Earnings Estimates for kneat.com

kneat.com logo with Medical background

Key Points

  • Cormark analysts have reduced kneat.com’s FY2026 earnings estimates to $0.00 per share, down from a previous estimate of $0.03.
  • Raymond James Financial has adjusted its price target for kneat.com shares from C$7.50 to C$7.00, while maintaining an "outperform" rating.
  • Currently, kneat.com's stock is trading at C$5.90, having declined by C$0.12 during recent trading sessions.
  • Want stock alerts on kneat.com? Get 5 Weeks of MarketBeat All Access for $5. Get My Stock Alerts.

kneat.com, inc. (TSE:KSI - Free Report) - Research analysts at Cormark decreased their FY2026 earnings estimates for kneat.com in a research note issued on Thursday, August 7th. Cormark analyst G. Fairweather now forecasts that the company will earn $0.00 per share for the year, down from their previous forecast of $0.03. The consensus estimate for kneat.com's current full-year earnings is ($0.12) per share. Cormark also issued estimates for kneat.com's FY2027 earnings at $0.08 EPS.

Separately, Raymond James Financial dropped their price objective on shares of kneat.com from C$7.50 to C$7.00 and set an "outperform" rating on the stock in a research note on Wednesday.

View Our Latest Analysis on KSI

kneat.com Price Performance

TSE:KSI traded down C$0.12 during trading hours on Friday, reaching C$5.90. 21,448 shares of the company traded hands, compared to its average volume of 89,550. kneat.com has a 1-year low of C$4.40 and a 1-year high of C$7.25. The stock has a market cap of C$551.66 million, a P/E ratio of -63.73, a P/E/G ratio of 597.67 and a beta of 1.08. The firm's 50-day moving average is C$6.04 and its 200-day moving average is C$6.27. The company has a debt-to-equity ratio of 85.50, a current ratio of 1.43 and a quick ratio of 1.50.

kneat.com Company Profile

(Get Free Report)

kneat.com Inc is in the business of developing and marketing a software application for modelling regulated data-intensive processes for regulated industries, focusing on the life sciences industry. The company has developed Kneat Gx solution which provides management real-time visibility and control and increases product, quality, and compliance.

Recommended Stories

Earnings History and Estimates for kneat.com (TSE:KSI)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in kneat.com Right Now?

Before you consider kneat.com, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and kneat.com wasn't on the list.

While kneat.com currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

7 Energy Stocks to Buy and Hold Forever Cover

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

3 Buy-the-Dip Stocks Poised to Rebound Soon
Quantum Boom: 3 Strong Picks with Lower Risk
3 Overlooked AI Stocks That Chipmakers Can’t Live Without

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines